A Clinical Study on the Analysis of Risk Factors for the Occurrence of PD-1/PD-L1 Inhibitor-associated Liver Injury in Lung Cancer Patients

This observational study is looking at what factors put lung cancer patients at higher risk of developing serious side effects from immunotherapy drugs (PD-1/PD-L1 inhibitors). It collects data from patients already receiving these treatments to identify patterns and risk factors. **You may be eligible if...** - You have been diagnosed with lung cancer - You have received at least one course of a PD-1 or PD-L1 inhibitor (a type of immunotherapy) - You are between 18 and 80 years old **You may NOT be eligible if...** - You had significant liver injury before starting immunotherapy (liver enzyme levels more than 5 times the normal limit) - Your doctor believes your participation in the study would not be appropriate for you personally Talk to your doctor to see if this trial is right for you.